
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/8326/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:10:20 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--8326 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--8326 block--content--website-notice-block block--content--website-notice-block--8326 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--8326 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--8326 block--content--system-main-block block--content--system-main-block--8326 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--8326 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001157523-21-000791.rtf%3b%20filename_%3dUTF-8%27%270001157523-21-000791.rtf" type="application/rtf" title="0001157523-21-000791.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001157523-21-000791.pdf%3b%20filename_%3dUTF-8%27%270001157523-21-000791.pdf" type="application/pdf" title="0001157523-21-000791.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001157523-21-000791.xls%3b%20filename_%3dUTF-8%27%270001157523-21-000791.xls" type="application/vnd.ms-excel" title="0001157523-21-000791.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001157523-21-000791.html" type="application/octet-stream" title="0001157523-21-000791-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srrk="http://scholarrock.com/20210615" xmlns="../../../www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: business wire
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_f0dcffc819e74809a1a2fd5bef6b42a6" contextRef="c20210615to20210615" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_caee4f94c0eb4b77aef3424fd5bf1571" contextRef="c20210615to20210615">0001727196</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="#srrk-20210615.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20210615to20210615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-15</xbrli:startDate><xbrli:endDate>2021-06-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div>
      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED









          STATES</span><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          SECURITIES AND EXCHANGE COMMISSION</span><br />
        <span style="font-weight: bold;">Washington, D.C. 20549</span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">FORM









          <ix:nonNumeric name="dei:DocumentType" id="Fact_309f31d31d6e4fb8ac1d289f41adf017" contextRef="c20210615to20210615">8-K</ix:nonNumeric></span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">CURRENT REPORT<br />
      </div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div>&#160;</div>

      <div style="text-align: center;">Date of Report (Date of earliest event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_5f36107b68764dcba614edf12ef39d3e" contextRef="c20210615to20210615" format="ixt:datemonthdayyearen">June 15, 2021</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_68811a2fa8e44f4484213de349f561a2" contextRef="c20210615to20210615">Scholar Rock Holding Corp</ix:nonNumeric>oration</span><br />
        (Exact Name of Registrant as Specified in Charter)</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z107cf8ce03914b7f865c0dfc5f27fdba">


  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_a906e03582db4501b6c541f4d818334b" contextRef="c20210615to20210615" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_8691faf920de483da499787ee977a4f2" contextRef="c20210615to20210615">001-38501</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_6121609152554dfbb7c2d794e9e413c6" contextRef="c20210615to20210615">82-3750435</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(I.R.S. Employer Identification Number)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_5992aafc22244d71a7abce6f5075e6c4" contextRef="c20210615to20210615">301 Binney Street</ix:nonNumeric><span style="font-weight: bold;">, </span><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_80fd242772024dddbc7c53e6ac31dd3c" contextRef="c20210615to20210615">3rd Floor</ix:nonNumeric><span style="font-weight: bold;">, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_00464dae8abb4d0280834a5e0d32fb4c" contextRef="c20210615to20210615">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_ae5ea94e672a4ceb9e66f59b7193b7ba" contextRef="c20210615to20210615">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_cb2c7206c136429fa4f708a4bd84ae47" contextRef="c20210615to20210615">02142</ix:nonNumeric></span></div>

        (Address of Principal Executive Offices) (Zip Code)</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_45f0f3d713e642eb9180def09abd3cc1" contextRef="c20210615to20210615">857</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_4e16b7b07a3a4b279d3c3185d7b97847" contextRef="c20210615to20210615">259-3860</ix:nonNumeric></span><br />
        (Registrant&#8217;s telephone number, including area code)</div>

      <div>&#160;</div>

      <div style="text-align: center;">(Former name or former address, if changed since last report)</div>

      <div>&#160;</div>

      <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

      <div>&#160;</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_c97d60879bb54793a5a43fe8773753ef" contextRef="c20210615to20210615" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Written










        communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_2c635c6c41f94566b56478ae1a98e33b" contextRef="c20210615to20210615" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Soliciting










        material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_53ca9dfd1ef7484da5cce86ad4c7904d" contextRef="c20210615to20210615" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement










        communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_1890a6dff35846eb8bef02e5ab27a2d3" contextRef="c20210615to20210615" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement










        communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

      <div>&#160;</div>

      <div>Securities registered pursuant to Section 12(b) of the Act:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z70d7d1ffb9404515954838ce95d0dafe">


  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_30c5ef033cd94451957a3076f36d6f10" contextRef="c20210615to20210615">Common Stock, par value $0.001 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_4b5518e169f54cfc9ef5eb2050db5bb6" contextRef="c20210615to20210615">SRRK</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_56c0fd431113498fbd1841717034fbe0" contextRef="c20210615to20210615" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>&#160;</div>

      <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company
        <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_db14ad5cfc0d4b7c97b558754ecfba7b" contextRef="c20210615to20210615" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
        Act.&#160; <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_3cab5d719bc14949b4a625f4186c40ae" contextRef="c20210615to20210615" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div>
        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01. Other Events.</div>

        <div>&#160;</div>

        <div style="text-align: left; text-indent: 22.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Scholar Rock Holding Corporation (the &#8220;Company) will host a Key Opinion Leader (KOL) event and panel discussion on Tuesday, June 15,
          2021 starting at 10:00 a.m. Eastern Time.</div>

        <div>&#160;</div>

        <div style="text-align: left; text-indent: 22.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A copy of the presentation slide deck that will be presented is being furnished as Exhibit 99.1 to this Report on Form 8-K. A live
          webcast of the presentation may be accessed by visiting the Investors &amp; Media section of the Company&#8217;s website at http://investors.scholarrock.com.</div>

        <div>&#160;</div>

        <div style="text-align: left; text-indent: 22.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed
          &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the
          Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</div>

        <div>&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01. Financial Statements and Exhibits.</div>

        <div>&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" id="z3298c69692e54c1aa25ac8ab2d688b95" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 9%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; margin-left: 9pt;">Exhibit</div>
                <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; margin-left: 18pt;">No.</div>
              </td>

    <td style="width: 1%; vertical-align: middle; white-space: nowrap;">&#160;</td>

    <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a52445497ex99_1.htm"><span style="text-decoration: underline;">99.1</span></a></div>
              </td>

    <td style="width: 1%; vertical-align: middle;">&#160;</td>

    <td style="width: 90%; vertical-align: middle;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a52445497ex99_1.htm"><span style="text-decoration: underline;">Presentation Slide
                      Deck, furnished hereto.</span></a></div>
              </td>

  </tr>


</table>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        </div>

        <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

        <div>&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
          undersigned hereunto duly authorized.</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" id="z9d4525d37869495d95be7a9dec282c38" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.11%; vertical-align: top;">&#160;</td>

    <td style="width: 50.89%; vertical-align: top;" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Scholar Rock Holding Corporation</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.11%; vertical-align: top;">&#160;</td>

    <td style="width: 2.77%; vertical-align: top;">&#160;</td>

    <td style="width: 48.12%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.11%; vertical-align: top;">&#160;</td>

    <td style="width: 2.77%; vertical-align: top;">&#160;</td>

    <td style="width: 48.12%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.11%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: June 15, 2021</div>
              </td>

    <td style="width: 2.77%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
              </td>

    <td style="width: 48.12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">/s/ Junlin Ho</span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.11%; vertical-align: top;">&#160;</td>

    <td style="width: 2.77%; vertical-align: top;">&#160;</td>

    <td style="width: 48.12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Junlin Ho</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.11%; vertical-align: top;">&#160;</td>

    <td style="width: 2.77%; vertical-align: top;">&#160;</td>

    <td style="width: 48.12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">General Counsel and Corporate Secretary</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

      </div>

    </div>

  </div>

</body>

<!-- Mirrored from investors.scholarrock.com/node/8326/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:10:20 GMT -->
</html>
</XBRL>
<div><a name="a52445497ex99_1.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: business wire
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div style="text-align: left;"><font style="font-weight: bold;">
      <title></title>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide1.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Apitegromab Positioned to be the Potential Next Transformative Therapy for Patients Suffering with
              SMA&#160;&#160;KOL Event and Panel DiscussionJune 15, 2021&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide2.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Disclaimers&#160;&#160;Various statements in this presentation concerning the future expectations, plans and
              prospects of Scholar Rock, Inc. (&#8220;Scholar Rock&#8221;), including without limitation, Scholar Rock&#8217;s expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting
              results from its clinical trials for its product candidates, its disease indication selection and timing for such selection, the ability of apitegromab (SRK-015) to affect the treatment of patients suffering from Spinal Muscular Atrophy (SMA)
              either as a monotherapy or in conjunction with the current standard of care, and the ability of SRK-181 to affect the treatment of cancer patients in a manner consistent with preclinical data constitute forward-looking statements for the
              purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;project,&#8221;
              &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to identify such forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result
              of various important factors, including, without limitation, preclinical and clinical data, including the 12-month top-line results from the Phase 2 trial of apitegromab, are not predictive of, are inconsistent with, or more favorable than,
              data generated from future clinical trials of the same product candidate, including the planned Phase 3 trial of apitegromab in SMA, Scholar Rock&#8217;s ability to provide the financial support, resources and expertise necessary to identify and
              develop product candidates on the expected timeline, information provided or decisions made by regulatory authorities differ from the company&#8217;s expectations, competition from third parties that are developing products for similar uses,
              Scholar Rock&#8217;s ability to identify and develop multiple product candidates on the expected timeline, the impacts of the COVID-19 pandemic, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property, Scholar Rock&#8217;s
              dependence on third parties for development and manufacture of product candidates including to supply any clinical trials, and Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its business
              activities and establish and maintain strategic business alliances and new business initiatives as well as those risks more fully discussed in the section entitled "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended
              March 31, 2021, which is on file with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange
              Commission. Any forward-looking statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. Scholar Rock explicitly disclaims any obligation to update any
              forward-looking statements unless required by law.&#169; Scholar Rock, Inc. All rights reserved. June 2021.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide3.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Agenda&#160;&#160;3&#160;&#160;Opening Remarks and Spinal Muscular Atrophy Treatment Landscape&#160;&#160;Tony
              KingsleyPresident &amp; CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Apitegromab TOPAZ Phase 2 Proof-of-Concept Trial ResultsApitegromab Phase 3 Trial Design Considerations&#160;&#160;&#160;&#160;Yung Chyung M.D.CMO&#160;&#160;Moderated byYung Chyung, M.D.&#160;&#160;Panel Discussion with TOPAZ Trial
              Investigators:Thomas Crawford, M.D. - Johns Hopkins MedicineBasil Darras, M.D. &#8211; Boston Children&#8217;s Hospital &amp; Harvard Medical School&#160;&#160;&#160;&#160;&#160;&#160;Jill Jarecki, Ph.D.CSO of Cure SMA&#160;&#160;Unmet Medical Needs of Individuals with SMA&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide4.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Apitegromab Shows Transformative Potential in Patients with Type 2 and 3 SMA&#160;&#160;&#160;&#160;Spinal Muscular
              Atrophy (SMA) remains a devastating and debilitating disease despite the utilization of SMN upregulatorsMulti-pronged approach may be needed in treating SMA; muscle-directed therapy may further improve motor functionApitegromab showed
              transformative potential in patients with Type 2/3 SMA thru the TOPAZ Phase 2 trialExciting potential path forward for apitegromabin a rational, targeted, and efficient Phase 3 trial&#160;&#160;4&#160;&#160;Apitegromab is an investigational product candidate
              that is currently being evaluated in a clinical development program for the treatment of SMA. Apitegromab has not been approved by the U.S. Food and Drug Administration (FDA), the European Commission, or any other health or regulatory
              authority. The safety and effectiveness of this molecule have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide5.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;5&#160;&#160;Spinal Muscular Atrophy Overview&#160;&#160;&#160;&#160;&#160;&#160;Significant, progressive motor functionimpairment; many
              lose ambulation&#160;&#160;Infantile onset; unable to sit upindependently&#160;&#160;Severe, progressive disabilities and unable to walk independently&#160;&#160;Type 114%&#160;&#160;Type 251%&#160;&#160;Type 335%&#160;&#160;Global disease with 30,000-35,000affected in U.S. and Europe alone&#160;&#160;&#160;&#160;TOPAZ*
              12-month results showed transformative potential in non-ambulatory Type 2 and 3 patients&#160;&#160;Represents ~2/3 of overall patient population&#160;&#160;&#160;&#160;Motor neuron impairment and loss due to SMN genetic deficiency, leading to muscle atrophy and
              weakness&#160;&#160;*TOPAZ Phase 2 trial evaluated patients with Type 2 and 3 SMA (did not include Type 1)Lallyet al, OrphanetJournal of Rare Diseases, 2017&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide6.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;6&#160;&#160;Potential to Pioneer a New Treatment Era: Opportunity forMuscle-Directed Therapy to Complement SMN
              Upregulators&#160;&#160;&#160;&#160;Phase 3Trial Design&#160;&#160;&#160;&#160;Indication&#160;&#160;&#160;&#160;MarketPenetration&#160;&#160;Non-ambulatory Type 2/32-12 years of agePrimary endpoint: Mean change from baseline in HFMSE at 15 months&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&gt;11,000* patients treated WW$2+ billion in revenues
              (LTM)&#160;&#160;~1,200*** patients treated WW~$1.1 billion in revenues (LTM)&#160;&#160;~3,000** patients treated WW~CHF135 million in revenues (LTM)&#160;&#160;Type 1, 2, and 3 SMA in pediatricand adult patients&#160;&#160;Type 1, 2, 3 SMA in patients 2 months of age and
              older&#160;&#160;SMA in patients less than 2 years ofage&#160;&#160;Non-ambulatory Type 2/32-25 years of agePrimary endpoint: Mean change from baseline in MFM-32 at 12 months&#160;&#160;Infantile-onset Type 1&lt;6 months of agePrimary endpoints: Ability to sit
              independently and event-free survival&#160;&#160;*As of 1Q21 financial update on 4/22/21; includes patients treated worldwide in post-marketing setting, expanded access program, and clinical trials.**As of 1Q21 financial update on 4/21/21; includes
              patients treated worldwide between clinical trials, commercial, and compassionate use program.***As of 1Q21 financial update on 4/27/21; commercially, via managed access programs and in clinical trials HFMSE = Hammersmith Functional Motor
              Scale Expanded; MFM-32 = Motor Function Measure &#8211; 32 items&#160;&#160;&#160;&#160;Patients continue to experience major functional impairments despite utilization of SMN upregulators&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide7.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Apitegromab: Muscle-Directed Therapy Aimed at Complementing SMN Upregulators&#160;&#160;7&#160;&#160;Myostatin is a
              negative regulatorof skeletal muscle growthApitegromab is a fully human, mAb that specifically binds to proforms of myostatin and inhibits myostatin activation&#160;&#160;Apitegromab is a muscle-directed approach aimed at improving motor
              function&#160;&#160;Adapted from images courtesy of the SMA Foundation&#160;&#160;Apitegromab&#160;&#160;SMN upregulators prevent further degeneration of motor neurons...but do not directly address muscle atrophy&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Motor neurondegeneration&#160;&#160;Muscle fiber
              atrophy&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide8.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cure SMA&#160;&#160;Jill Jarecki, PhDCSO&#160;&#160;&#160;&#160;June 15, 2021&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide9.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Cure SMA&#160;&#160;We fund groundbreaking research and provide families thesupport they need for today.Annual
              budget of $15M$85 Million in research funding 36 Chapters in the US9,000 affected individuals in membership database300 newly diagnosed contacts annuallyNewly diagnosed care and info packetsInfo on clinical trial recruitment4,000 families
              obtain services annuallyAnnual conference, with 2500 attendees&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide10.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;The Evolving Landscape in SMA&#160;&#160;The FDA-approval of 3 new therapies has revolutionized and dramatically
              changed the natural history of SMAEarly identification and treatment dramatically alter long-termoutcomes, most strikingly presymptomaticallySymptomatic treatment providing improvements through increases,stabilization, and slowingMany unmet
              needs remain when addressing the complexities of SMAUnmet need is higher in older patients compared to younger patients.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide11.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;45% of SMA Patients Remain Untreated at End of Q1 2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Percent of SMA
              Patients&#160;&#160;70%60%50%40%30%20%10%0%17Q1 Q2 Q3 Q4 18Q1 Q2 Q3 Q4 19Q1 Q2 Q3 Q4 20Q1 Q2 Q3 Q4 21Q1Year QuarterActuals through the end of Q1 2021, with projections for the three quarters after.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide12.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Almost Half of Those with SMA Type I Currently Sit without Support&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
              12.90&#160;&#160;%&#160;&#160;21.90&#160;&#160;%&#160;&#160;35.37&#160;&#160;%&#160;&#160;37.66&#160;&#160;%&#160;&#160;44.64&#160;&#160;%&#160;&#160; 87.10% &#160;&#160;78.08%&#160;&#160;64.63%&#160;&#160;62.30%&#160;&#160; 55.36% &#160;&#160;100%90%80%70%60%50%40%30%20%10%0%&#160;&#160;2017 (n=93)&#160;&#160;2019 (n=147)&#160;&#160;2020 (n=231)&#160;&#160;2021 (n=56)&#160;&#160;&#160;&#160;2018 (n=146)Sit without Support&#160;&#160;&#160;&#160;Cannot sit without
              support&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide13.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Can Stand With or Without Support Currently among SMA Type
              II&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10.94%&#160;&#160;11.44%&#160;&#160;17.05%&#160;&#160;18.36%&#160;&#160;89.06% 88.56%&#160;&#160;82.95%&#160;&#160;81.64%&#160;&#160;100%90%80%70%60%50%40%30%20%10%0%&#160;&#160;2017(n=265)&#160;&#160;2018(n=271)&#160;&#160;2019(n=258)&#160;&#160;2020(n=414)&#160;&#160;&#160;&#160;&#160;&#160;Can stand (with or without) support Cannot stand (with or without)
              support2017 &amp; 2018: Question was what is your maximum current motor function. Assumed able to stand with or without support if any of the following choices were picked: walk alone, walk with assist, cruise along furniture, stand without
              support, or stand with support;2019 &amp; 2020: Respondents were asked to answer yes or no if affected child could currently can stand with assistance or stand alone.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide14.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;What Comes Next - SMA is Not Cured Yet&#160;&#160;Need More Impact for older ages and stage of SMADifferent for
              symptomatic vs NBS patientsSlow to Stop to Reverse&#160;&#160;&#160;&#160;&#160;&#160;Reverse &#8211; Restore Function -FutureStop Progression &#8211; Prevent SymptomsSlower Progression -ImprovementNatural History - Untreated&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide15.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Unmet Needs that Future Therapies will Address &#8211; From Adults in the 2020 Community Update
              Survey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;75%&#160;&#160;75%&#160;&#160;81%80%&#160;&#160;71%&#160;&#160;29%&#160;&#160;89% 89%&#160;&#160;81%82%80%&#160;&#160;39%&#160;&#160;31%&#160;&#160;94%94%98%&#160;&#160;90%&#160;&#160;15%&#160;&#160;94% 94% 94%&#160;&#160;100%90%80%70%60%50%40%30%20%10%0%&#160;&#160;Reducing Fatigue&#160;&#160;Improving breathing function&#160;&#160;Improving swallowing&#160;&#160;Gaining muscle
              strength&#160;&#160;Achieving new motor function&#160;&#160;Improving Improving&#160;&#160;communication activities of daily&#160;&#160;through speech living and/or technology&#160;&#160;&#160;&#160;Type I&#160;&#160;&#160;&#160;Type II&#160;&#160;&#160;&#160;Type III&#160;&#160;&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide16.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;NeuroprotectionNeural transmissionRegenerative targetsMuscle enhancementApitegromab - Scholar
              RockGenetic modifiersCombinations of above with SMNenhancer&#160;&#160;Therapeutic Strategies &#8211; SMN Independent&#160;&#160;&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide17.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Thank You!&#160;&#160;&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide18.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cure SMA&#160;&#160;Jill Jarecki, PhDCSO&#160;&#160;&#160;&#160;June 15, 2021&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide19.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Apitegromab Showed Transformative Potential in SMA Phase 2 Trial&#160;&#160;Yung Chyung, M.D.Chief Medical
              Officer&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide20.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;TOPAZ: Evolving Understanding of Apitegromab&#8217;sTransformative Potential in Type 2 and Type 3
              SMA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;June 2021Additional Analyses&#160;&#160;April 202112-month top-line&#160;&#160;October 20206-month interim&#160;&#160;Showed Initial Proof-of-Concept&#160;&#160;Interim data showed the therapeutic potential of apitegromab in Type 2 and 3 SMA as add-on therapy to
              background nusinersenHFMSE increases in patients who had already received on average ~2 years of background nusinersen therapyMeaningful HFMSE gains over 6-month time frame&#160;&#160;Further Support for Efficacy Signal&#160;&#160;Largest HFMSE increases in
              non-ambulatory Type 2 and 3 patients; represents ~2/3 of SMA prevalenceDurability of effect with continued improvement in a subset of patientsSupports advancing to a Phase 3 trialAnticipated focus on patients with non- ambulatory Type 2 and
              3&#160;&#160;2021&#160;&#160;&#8730;&#160;&#160;&#160;&#160;&#160;&#160;&#8730;&#160;&#160;&#8730;&#160;&#160;Additional exploratory analyses to be presented at future medical congresses&#8230;&#160;&#160;Further Support TherapeuticPotential and Phase 3 Plans&#160;&#160;Additional insights from exploratory analyses offer deeper understanding of
              apitegromab&#8217;s potential profile:Age of patientsDuration of prior background therapySecondary efficacy endpoint (WHO Motor Milestones)&#160;&#160;20&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide21.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;21&#160;&#160;TOPAZ Top-Line Data Showed Apitegromab&#8217;sTransformative Potential in Patients with Type 2/3 SMA&#160;&#160;&#10004;
              Apitegromab treatment (as add-on to background nusinersen) led to improvements inHFMSE in both non-ambulatory cohorts&#160;&#160;* Pooled cohorts of non-ambulatory patients treated with apitegromab 20 mg/kg and 2 mg/kg**Non-ambulatory patients who
              initiated background nusinersen at a young age of &lt;5 years and treated with apitegromab 20 mg/kg dose&#160;&#160;At 12 months&#160;&#160;Mean HFMSE increase&#160;&#160;&#8805;1-point increase&#160;&#160;&#8805;3-point increase&#160;&#160;Initiated background nusinersen age &lt;5**&#160;&#160;+7.1 points&#160;&#160;88%
              (7/8) of patients&#160;&#160;63% (5/8) of patients&#160;&#160;Initiated background nusinersen age &#8805;5&#160;&#160;+0.6 points&#160;&#160;64% (9/14) of patients&#160;&#160;29% (4/14) of patients&#160;&#160;&#10004; Majority of non-ambulatory patients observed a clinical improvement in
              HFMSE*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20151050-5-10&#160;&#160;HFMSE change from baseline&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide22.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;Evaluating range of exploratory analyses to better understand the therapeutic responseInitial
              findings from non-ambulatory cohorts:HFMSE improvements observed across age range with relatively larger gains from earlier treatmentDuration of prior nusinersen treatment not correlated with HFMSE increaseProvides further support that
              improvements may be attributable to apitegromabPatients were already in chronic maintenance phase of nusinersen at enrollmentAchievement by some patients of WHO motor milestones (additional high bar efficacy endpoint) further shows
              apitegromab&#8217;s potentialTotal of 7 patients gained new WHO motor milestones across both non-ambulatory cohorts1 patient* gained 3 milestones (hands &amp; knees crawling, standing with assistance, walking with assistance)1 patient** gained 2
              new milestones (hands &amp; knees crawling, standing with assistance)Phase 3 trial in patients with non-ambulatory Type 2 and 3 anticipated to initiate by end of 2021*initiated nusinersen age &lt;5, apitegromab 20 mg/kg 22**initiated
              nusinersen age &#8805;5&#160;&#160;Additional TOPAZ Analyses Further SupportApitegromab&#8217;s Potential to Improve Motor Function&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide23.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;23&#160;&#160;Expectations for Patients on BackgroundSMN Upregulator Therapy&#160;&#160;Yung Chyung, M.D. Chief Medical
              Officer&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide24.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Patients with Type 2 and 3 SMA Continue to Experience MajorFunctional Deficits Despite Improvement
              from Nusinersen&#160;&#160;24&#160;&#160;Darras, B., et.al. Nusinersen in later-onset spinal muscular atrophy. Neurology. May 2019; 92 (21) e2492-e2506.This third-party information is provided for background only and is not intended to convey or imply a
              comparison to the TOPAZ clinical trial results.&#160;&#160; 3.9-point increase in&#160;&#160;HFMSE from nusinersen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0Mean improvement in HFMSE experienced by patients withnon-ambulatory Type 2/3 SMA in nusinersen Phase 3 CHERISH trial&#160;&#160;20&#160;&#160;40&#160;&#160;HFMSE Score
              at Month 15&#160;&#160;&#160;&#160;80Total Possible HFMSE Scoreof 6660&#160;&#160;&#160;&#160;SMN upregulator treated patients continue to experience major functional deficits&#8230;&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide25.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#8224;Mercuri E, et.al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J
              Med. 2018;378:625-635.This third-party information is provided for background only and is not intended to convey or imply a comparison to the TOPAZ clinical trial results.&#160;&#160;CHERISH Trial in Non-Ambulatory Type 2/3 SMA&#8224;&#160;&#160;Majority of patients
              treated with nusinersen after the age of 5 did not observe an improvement&#160;&#160;Nusinersen Does Not Increase HFMSE on Average inChildren Who Initiate Treatment After the Age of 5 Years&#160;&#160;25&#160;&#160;&#160;&#160;&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide26.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Plateauing of HFMSE Increases Observed After First 15Months of Nusinersen Treatment in Type 2 and 3
              SMA&#160;&#160;26&#160;&#160;&#8220;Longer-term treatment with nusinersen: results in later-onset spinal muscular atrophy from the SHINE study&#8221; P.257, World Muscle Society Congress 2020This third-party information is provided for background only and is not intended to
              convey or imply a comparison to the TOPAZ clinical trial results.&#160;&#160;&#160;&#160;Most nusinersen-treated patients in CHERISH were &lt;5 years of age at therapy initiation&#160;&#160;Mean (+ SE) Change in HFMSE Total Score From Baseline&#160;&#160;1 92 169 253 350 450&#160;&#160;690
              930Analysis Visit, days&#160;&#160;1170&#160;&#160;1410&#160;&#160;1650&#160;&#160;876543210-1-2-3-4&#160;&#160;&#160;&#160;&#160;&#160;Nusinersen observed plateauing of improvement during chronic maintenance phase&#8230;&#160;&#160;&lt;1-point increase in HFMSE afterfirst year of treatment&#160;&#160;+3.9-points&#160;&#160;+4.6-points&#160;&#160;Unmet
              Need for Motor Function Gains&#160;&#160;&#160;&#160;Initial treatmentCHERISH&#160;&#160;&#160;&#160;Chronic maintenance phaseSHINE&#160;&#160;&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide27.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;27&#160;&#160;Review of Positive TOPAZ Top-Line Results&#160;&#160;Yung Chyung, M.D. Chief Medical Officer&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide28.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;Apitegromab Phase 2 Trial Design&#160;&#160;28&#160;&#160;&#160;&#160;Patients with Type 2 and 3 SMA&#160;&#160;&#160;&#160;Ambulatory Type 3
              patients (ages 5-21)Apitegromab 20 mg/kg IV Q4W monotherapy or withchronic nusinersen maintenance&#160;&#160;Key objectives: RHS and safety at 12 months&#160;&#160;Non-ambulatory Type 2 patients (ages &#8805;2) on chronicmaintenance nusinersen (initiated &lt;5 years
              of age)Apitegromab 2 mg/kg and 20 mg/kg IV Q4W + nusinersen&#160;&#160;Key objectives: HFMSE and safety at 12 months&#160;&#160;Non-ambulatory Type 2/3 patients (ages 5-21) on chronicmaintenance nusinersen (initiated &#8805;5 years of age)Apitegromab 20 mg/kg IV Q4W +
              nusinersen&#160;&#160;Key objectives: HFMSE and safety at 12 months&#160;&#160;&#160;&#160;Patients on background SMN therapy were in chronic maintenance phase of nusinersen(~5 mean maintenance doses at baseline)&#160;&#160;*Excludes one patient from Cohort 1 that discontinued from
              the trial&#160;&#160;All 57* patients who completed the 12-month trial elected to opt into the extension period&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide29.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Baseline CharacteristicsNusinersen-treated patients well into chronic maintenance
              phase&#160;&#160;29&#160;&#160;&#160;&#160;Non-Ambulatory,Ages &#8805;2 and initiated nusinersen &lt;5 years&#160;&#160;&#160;&#160;&#160;&#160;Non-Ambulatory,Ages 5-21&#160;&#160;Ambulatory,Ages 5-21&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20 mg/kg+nusinersen&#160;&#160;2 mg/kg+nusinersen&#160;&#160;Pooled&#160;&#160;20 mg/kg+nusinersen&#160;&#160;20 mg/kg monotherapy&#160;&#160;20
              mg/kg+nusinersen&#160;&#160;Pooled&#160;&#160;N&#160;&#160;10&#160;&#160;10&#160;&#160;20&#160;&#160;15&#160;&#160;11&#160;&#160;12&#160;&#160;23&#160;&#160;Mean age at baseline (min, max)&#160;&#160;3.8 (2, 6)&#160;&#160;4.1 (2, 6)&#160;&#160;4.0 (2, 6)&#160;&#160;11.7 (8, 19)&#160;&#160;12.1 (7, 19)&#160;&#160;13.1 (7, 21)&#160;&#160;12.6 (7, 21)&#160;&#160;Mean RHS score (min, max)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;47.6 (26, 63)&#160;&#160;51.3 (43,
              62)&#160;&#160;49.6 (26, 63)&#160;&#160;Mean HFMSE score (min, max)&#160;&#160;23.5 (14, 42)&#160;&#160;26.1 (12, 44)&#160;&#160;24.8 (12, 44)&#160;&#160;22.7 (13, 39)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mean # of nusinersen maintenance doses (min, max)&#160;&#160;5.4 (3, 8)&#160;&#160;5.5 (2, 9)&#160;&#160;5.5 (2, 9)&#160;&#160;5.1 (2, 9)&#160;&#160;N/A&#160;&#160;5.6 (2, 8)&#160;&#160;N/A&#160;&#160;SMN2
              Gene Copy* (#, %)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2&#160;&#160;1 (10%)&#160;&#160;1 (10%)&#160;&#160;2 (10%)&#160;&#160;&#160;&#160;1 (9%)&#160;&#160;0 (0%)&#160;&#160;1 (4%)&#160;&#160;3&#160;&#160;8 (80%)&#160;&#160;8 (80%)&#160;&#160;16 (80%)&#160;&#160;11 (73%)&#160;&#160;4 (36%)&#160;&#160;9 (75%)&#160;&#160;13 (57%)&#160;&#160;4&#160;&#160;0 (0%)&#160;&#160;1 (10%)&#160;&#160;1 (5%)&#160;&#160;2 (13%)&#160;&#160;4 (36%)&#160;&#160;1 (8%)&#160;&#160;5
              (22%)&#160;&#160;Discontinuation(s)&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;1**&#160;&#160;1**&#160;&#160;*Data not available for all patients**Patient who discontinued study for reasons unrelated to study drug HFMSE=Hammersmith Functional Motor Scale Expanded; RHS=Revised Hammersmith
              Scale&#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide30.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Patients Enrolled in TOPAZ Already in Chronic MaintenancePhase of Nusinersen Treatment&#160;&#160;30&#160;&#160;*Reflects
              non-ambulatory cohorts in TOPAZ**The HFMSE time course plot for background nusinersen effect is hypothetical and intended for illustrative purposes only. The data presented here do not reflect any cross-trial comparisons. TOPAZ was not a
              placebo-controlled trial, it is not possible to draw direct conclusions in relation to background nusinersen effects alone.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Time**&#160;&#160;Initial treatment phase of nusinersen&#160;&#160;Chronic maintenance phase ofnusinersen&#160;&#160;HFMSE&#160;&#160;TOPAZ patients
              in chronic maintenance phase of nusinersen therapy~2 years at enrollment~3 years at 12-month efficacy timepointTOPAZ baseline meanHFMSE score*: 22.7-26.1&#160;&#160;CONCEPTUAL&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide31.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Non-Ambulatory Type 2 Cohort:Initiated nusinersen age &lt;5&#160;&#160;31&#160;&#160;Apitegromab (20 mg/kg) +
              nusinersen&#160;&#160;n=8&#160;&#160;Mean change from baseline in HFMSE(95% CI)&#160;&#160;+7.1(1.8, 12.5)&#160;&#160;# (%) patients achieving:&#160;&#160;&#160;&#160;&#8805;1-pt increase in HFMSE&#160;&#160;7/8 (88%)&#160;&#160;&#8805;3-pt increase in HFMSE&#160;&#160;5/8 (63%)&#160;&#160;&#8805;5-pt increase in HFMSE&#160;&#160;5/8 (63%)&#160;&#160;Baseline characteristics:
              mean (min, max)&#160;&#160;n=10&#160;&#160;Age&#160;&#160;3.8 (2, 6)&#160;&#160;HFMSE score&#160;&#160;23.5 (14, 42)&#160;&#160;# of nusinersen maintenance doses&#160;&#160;5.4 (3, 8)&#160;&#160;Sizable increases in HFMSE observed in patients already treated with chronic maintenance nusinersen88% (7/8) improved63% (5/8)
              with &#8805;5-point increase38% (3/8) with &gt;10-point increaseContinuous and durable improvements observed through 12-months of treatment&#160;&#160;&#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide32.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Non-Ambulatory Type 2/3 Cohort:Initiated nusinersen age &#8805;5&#160;&#160;Apitegromab (20 mg/kg) + nusinersen&#160;&#160;Per
              Protocol Population* (n=13)&#160;&#160;Intent-to-Treat Population (n=14)&#160;&#160;Mean change from baseline in HFMSE (95% CI)&#160;&#160;+1.2(-0.5, 2.9)&#160;&#160;+0.6(-1.4, 2.7)&#160;&#160;# (%) patients achieving:&#160;&#160;&#160;&#160;&#160;&#160;&#8805;1-pt increase in HFMSE&#160;&#160;9/13 (69%)&#160;&#160;9/14 (64%)&#160;&#160;&#8805;3-pt increase in
              HFMSE&#160;&#160;4/13 (31%)&#160;&#160;4/14 (29%)&#160;&#160;&#8805;5-pt increase in HFMSE&#160;&#160;2/13 (15%)&#160;&#160;2/14 (14%)&#160;&#160;Baseline characteristics: mean (min, max)&#160;&#160;n=15&#160;&#160;&#160;&#160;Age&#160;&#160;11.7 (8, 19)&#160;&#160;&#160;&#160;HFMSE score&#160;&#160;22.7 (13, 39)&#160;&#160;&#160;&#160;# of nusinersen maintenance doses&#160;&#160;5.1 (2,
              9)&#160;&#160;&#160;&#160;32&#160;&#160;Majority of patients improved in HFMSE (despite initiating background nusinersen age &#8805;5)~2/3 with &#8805;1-point increase~30% with &#8805;3-point increaseDurability of effect observedthrough 12-months of treatment&#160;&#160;&#160;&#160;*Patient had concomitant
              exposure to an acetylcholinesterase inhibitor, which was not permitted per the TOPAZ trial protocolData on file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide33.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;TOPAZ Results SuppPhase 3 Trial&#160;&#160;ort Evaluation&#160;&#160;of Apitegromab&#160;&#160;in&#160;&#160;Treatment-emergent adverse events
              (TEAEs)&#160;&#160;Apitegromab 2 mg/kg (n=10)&#160;&#160;Apitegromab 20 mg/kg (n=48)&#160;&#160;Total (n=58)&#160;&#160;Any TEAE&#160;&#160;9 (90.0%)&#160;&#160;44 (91.7%)&#160;&#160;53 (91.4%)&#160;&#160;Any Serious TEAE&#160;&#160;1 (10.0%)&#160;&#160;4 (8.3%)&#160;&#160;5 (8.6%)&#160;&#160;Any TEAE leading to study drug discontinuation&#160;&#160;0 (0.0%)&#160;&#160;1
              (2.1%)&#160;&#160;1 (1.7%)&#160;&#160;Any Grade 3 (severe) or higher TEAE&#160;&#160;0 (0.0%)&#160;&#160;3 (6.2%)&#160;&#160;3 (5.2%)&#160;&#160;33&#160;&#160;Treatment-emergent adverse events (TEAEs) are defined as AEs that start after the first dose of study drug or start prior to the administration of study
              drug and worsen in severity/grade or relationship to investigational medication after the administrat ion of study drug.*TEAE rates are across all patients in TOPAZ trialData on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;&#160;&#160;Five most frequently
              reported TEAEs*: Headache (24%), pyrexia (22%), upper respiratory tract infection (22%), cough (22%), and nasopharyngitis (21%).SAEs, Grade 3 AEs and AE leading to early study discontinuation were all assessed by investigators as unrelated to
              study drugAnti-drug antibodies (ADA) were present at low titers following apitegromab treatment in 3 out of 58 enrolled patients. No apparent impact on drug exposure was observed and was not associated with any hypersensitivity
              reactions.Incidence and severity of AEs were consistent with the underlying patient population and background therapy&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide34.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Serious and Severe Treatment-Emergent Adverse Events(TEAEs)&#160;&#160;34&#160;&#160;Treatment-emergent adverse events
              (TEAEs) are defined as AEs that start after the first dose of study drug or start prior to the administration of study drug and worsen in severity/grade or relationship to investigational medication after the administration of study drug.
              Data on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;Serious TEAEs; All Assessed by Trial Investigators as Unrelated to Apitegromab&#160;&#160;2 mg/kg:Cohort 3: 1 patient hospitalized due to adenoidal and tonsillar hypertrophy and scheduled
              adenotonsillectomy (Grade 2).Resolved without sequelae.20 mg/kg:Cohort 1: 2 patients with gait inability considered a significant disability (both Grade 3). Events remain ongoing.Cohort 1: 1 patient hospitalized with post lumbar puncture
              syndrome (Grade 2). Resolved without sequelae.Cohort 1: 1 patient hospitalized due to viral upper respiratory infection (Grade 2/prior history). Resolved without sequelae.&#160;&#160;Other Severe TEAE; Assessed by Trial Investigator as Unrelated to
              Apitegromab&#160;&#160;Cohort 1: 1 patient presented with post lumbar puncture syndrome (non-serious Grade 3). Resolved without sequelae.&#160;&#160;Study Discontinuation; Assessed by Trial Investigator as Unrelated to Apitegromab&#160;&#160;Cohort 1: 1 patient withdrew
              consent after ~2 months in the trial. Grade 2 leg muscle fatigue (developed prior to enrollment).&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide35.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;35&#160;&#160;Additional Exploratory Analyses Further Support Apitegromab&#8217;s Potential Additive Benefit on Top
              of Nusinersen&#160;&#160;Yung Chyung, M.D.Chief Medical Officer&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide36.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;HFMSE Improvements Observed Across Age Range of Non-AmbulatoryPatients with Relatively Larger Gains
              from Earlier Treatment&#160;&#160;*Pooled cohorts of non-ambulatory patients treated with apitegromab 20 mg/kg and 2 mg/kg; excludes 4 patients who each missed 3 doses of apitegromab due to COVID-19-related site access restrictions and were not
              included in the primary (intent-to-treat) analysis.Data on file. Scholar Rock, Inc. Cambridge, MA&#160;&#160;HFMSE change from baseline&#160;&#160;Youngest(2 years)&#160;&#160;Oldest(19 years)&#160;&#160;&#160;&#160;Age of patient at baseline in TOPAZ&#160;&#160;36&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide37.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Increases in HFMSE Not Correlated with Duration of PriorNusinersen Treatment&#160;&#160;Change in HFMSE Not
              Correlated With Number ofNusinersen Maintenance Doses(post-hoc analysis of TOPAZ non-ambulatory patients)&#160;&#160;Further data suggesting increases inHFMSE may be attributable to apitegromab&#160;&#160;No correlation between duration of priornusinersen
              treatment and change in HFMSEPatients in TOPAZ were already in chronicmaintenance phase of nusinersen (mean of~2 years at enrollment)&#160;&#160;Data on file. Scholar Rock, Inc. Cambridge,
              MA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-10&#160;&#160;-5&#160;&#160;0&#160;&#160;5&#160;&#160;10&#160;&#160;15&#160;&#160;20&#160;&#160;HFMSE change from baseline&#160;&#160;&#160;&#160;2(~10 months)&#160;&#160;9(~3 years)&#160;&#160;&#160;&#160;# of maintenance nusinersen doses5(~2 years)&#160;&#160;37&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide38.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Clinical Outcome Measures: Progressive Levels of Difficultyin Measuring Gross Motor
              Functions&#160;&#160;38&#160;&#160;WHO Motor Milestones &#8211; Different and MoreChallenging Tests of Self-Sufficient Locomotion&#160;&#160;6 gross motor skills considered to be universal*&#160;&#160;Sitting without support &#8211; head erect for at least 10seconds; no use of arms or hands to
              balanceHands and knees crawling &#8211; at least 3 movements in a row and stomach does not touch supporting surfaceStanding with assistance &#8211; upright on both feet for at least 10 seconds without leaning on any objectWalking with assistance &#8211; takes
              at least 5 steps holding astable objectStanding alone &#8211; at least 10 seconds with no contact withperson or objectWalking alone &#8211; takes at least 5 steps independently&#160;&#160;&#160;&#160;HFMSE - Validated Regulatory EndpointUsed in SMA Trials&#160;&#160;33 distinct
              measures of an individual&#8217;s abilityto perform various activitiesTotal achievable score of 66Quality and execution of each movement is ranked on a scale of 0, 1, 2&#160;&#160;0 - cannot perform the task1 &#8211; can perform task but with adaptation2 &#8211; can
              perform task&#160;&#160;Examples of HFMSE tasks:&#160;&#160;Raising hand(s) to head in sittingLifting head from proneRolls prone to supineHigh kneeling to half kneelAscending/descending 4 stairs&#160;&#160;For complete descriptions of the 6 WHO motor development
              milestones, please refer to https://cdn.who.int/media/docs/default -source/child- growth/child-growth-standards/indicators/motor-development-milestones/assessment-of-gross-motor-development-in-the-who-
              multicentre-growth-reference-study.pdf?sfvrsn=81277ea7_0&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide39.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;WHO Motor DevelopmSupport Apitegromab&#8217;&#160;&#160;ent Milestos Potentia&#160;&#160;ne Achievemenl to Improve Mot&#160;&#160;ts
              Furtheror Function&#160;&#160;Non-ambulatory Type 2/3 Patients&#160;&#160;Pooled, 20 mg/kg&#160;&#160;Initiated nusinersen age &lt;5&#160;&#160;Initiated nusinersen age &#8805;5&#160;&#160;# of patients gaining &#8805;1 WHO motor milestone(s)&#160;&#160;7/35&#160;&#160;4/10&#160;&#160;3/15&#160;&#160;39&#160;&#160;WHO motor milestone analysis included
              all patients who completed the 12-month treatment period, including 4 patients who missed 3 doses of apitegromab due to COVID-19-related site access restrictions. Median baseline score for both non-ambulatory cohorts was 1.0.1 patient
              (initiated nusinersen age &#8805;5) gained 2 new motor milestones and 1 patient (initiated nusinersen age &lt;5, 20 mg/kg) gained 3 new motor milestonesPictures are not of patients with SMA and are not meant to be representative of patients with
              SMA. Data on file. Scholar Rock, Inc. Cambridge, MA.&#160;&#160;&#160;&#160;&#160;&#160;Sitting without support&#160;&#160;&#160;&#160;&#160;&#160;Hands &amp; knees crawling&#160;&#160;&#160;&#160;&#160;&#160;Standing with assistance&#160;&#160;&#160;&#160;&#160;&#160;Walking with assistance&#160;&#160;&#160;&#160;&#160;&#160;Standing alone&#160;&#160;&#160;&#160;&#160;&#160;Walkingalone&#160;&#160;&#10004;&#10004;&#160;&#160;&#10004;&#10004;&#10004;&#160;&#160;&#10004;&#10004;&#10004;&#160;&#160;&#10004;&#160;&#160;&#10004;&#160;&#160;Following
              12 months ofapitegromab treatment...&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide40.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Apitegromab to Advanceto Phase 3 Trial in Patients with Non-Ambulatory Type 2/3 SMA&#160;&#160;Yung Chyung,
              M.D.Chief Medical Officer&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide41.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;41&#160;&#160;Initial Development Strategy Focuses on Non- Ambulatory Patients on Background SMN
              Upregulators&#160;&#160;Global disease with30,000-35,000 affected inU.S. and Europe alone&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A&#160;&#160;&#160;&#160;Ambulatory patients&#160;&#160;Smaller population but high unmet need as benefits of SMN regulators not well-establishedTOPAZ suggests potential clinical
              benefit in a subset of patients&#160;&#160;&#160;&#160;&#160;&#160;C&#160;&#160;&#160;&#160;Type 1 patients, including those treated with gene therapyHighest incidence population and growing prevalence due toSMN upregulator treatmentTOPAZ showed benefits of early treatment
              suggestingpotential in Type 1 patients&#160;&#160;&#160;&#160;&#160;&#160;B&#160;&#160;&#160;&#160;Type 114%&#160;&#160;Type 251%&#160;&#160;Type 335%&#160;&#160;Apitegromab in non-ambulatory Type 2 and 3 with background SMN upregulatorsRepresents 2/3 of overall patientsMany patients already treated with or areeligible
              for SMN upregulator therapyImprovements in motor function on top of SMN upregulators observed in TOPAZ&#160;&#160;&#160;&#160;Anticipated Focus of Phase 3 Trial&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide42.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;42&#160;&#160;Preliminary Thoughts on Apitegromab Phase 3 Trial Design&#160;&#160;Design&#160;&#160;Subjects&#160;&#160;Key
              Objectives&#160;&#160;Timeline&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-ambulatory Type 2 and Type 3 SMAPediatric population in chronic maintenance phase of SMN therapy&#160;&#160;HFMSESafety&#160;&#160;Aim to initiate by end of 2021&#160;&#160;Randomized, double-blind, placebo-controlled12-month treatment
              periodApitegromab IV Q4W as add-on to nusinersen or risdiplamTOPAZ data support investigation of up to 20 mg/kg&#160;&#160;&#160;&#160;Apitegromab recently received Fast Track (FDA) and PRIME (EMA)designations, recognizing unmet medical needs in SMA&#160;&#160;Phase 3
              trial design subject to regulator interactions and feedback&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide43.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;43&#160;&#160;Additional Opportunities May Be Pursued With Separate Development Strategies&#160;&#160;Global disease
              with30,000-35,000 affected inU.S. and Europe alone&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Ambulatory patients&#160;&#160;Smaller population but high unmet need as benefits of SMN regulators not well-establishedTOPAZ suggests potential clinical benefit in a subset of
              patients&#160;&#160;C&#160;&#160;&#160;&#160;Type 1 patients, including those treated with gene therapyHighest incidence population and growing prevalence due toSMN upregulator treatmentTOPAZ showed benefits of early treatment suggestingpotential in Type 1
              patients&#160;&#160;&#160;&#160;B&#160;&#160;&#160;&#160;Type 114%&#160;&#160;Type 251%&#160;&#160;Type 335%&#160;&#160;Apitegromab in non-ambulatory Type 2 and 3 with background SMN upregulatorsRepresents 2/3 of overall patientsPatients already treated with or eligible forSMN upregulator therapyImprovements in
              motor function on top of SMN upregulators observed in TOPAZ&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide44.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;Panel Discussion onApitegromab&#8217;s Therapeutic Potential in SMA&#160;&#160;Thomas Crawford, M.D.Johns Hopkins
              Medicine&#160;&#160;Basil Darras, M.D.Boston Children&#8217;s HospitalHarvard Medical School&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide45.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Esteemed Panelists: TOPAZ Trial Investigators&#160;&#160;Member of the Department of Neurology at Johns Hopkins
              since 1987.Practice involves general child neurology with a principal interest in caring for children with neuromuscular, neuromotor, and ataxic disorders.On the Medical and Scientific Advisory Boards of Families of Spinal Muscular Atrophy,
              and theMedical Advisory Committee for the MuscularDystrophy Association.&#160;&#160;Thomas Crawford, MDCo-Director, MDA Clinic and Professorof Neurology and Pediatrics, Johns Hopkins MedicineLead TOPAZ Principal Investigator&#160;&#160;Chief of the division of
              clinical neurology in the Department of Neurology at Boston Children&#8217;s Hospital.Director of Neuromuscular Center and SpinalMuscular Atrophy program.Special focus is in the care of children with neuromuscular conditions originating from
              inherited or acquired conditions of the motor unit.&#160;&#160;Basil Darras, MDAssociate Neurologist-in-Chief, Boston Children&#8217;s Hospital and Professor of Neurology, Harvard Medical SchoolTOPAZ Trial Investigator&#160;&#160;45&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide46.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Thank You for Participating!&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pictures of individuals with SMA courtesy of Cure SMA 46&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide47.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Appendix&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide48.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Majority of Ambulatory Patients Maintained or Improved inRHS Score from Baseline&#160;&#160;48&#160;&#160;&#160;&#160;Apitegromab
              20 mg/kg monotherapy&#160;&#160;Apitegromab 20 mg/kg + nusinersen&#160;&#160;Mean change from baseline in RHS (95% CI)&#160;&#160;-0.4 (-3.9, 3.1)&#160;&#160;-0.3 (-2.0, 1.4)&#160;&#160;# (%) patients achieving:&#160;&#160;&#160;&#160;&#160;&#160;&#8805;0-pt increase in RHS&#160;&#160;6/11 (55%)&#160;&#160;7/12 (58%)&#160;&#160;&#8805;1-pt increase in RHS&#160;&#160;4/11
              (36%)&#160;&#160;5/12 (42%)&#160;&#160;&#8805;3-pt increase in RHS&#160;&#160;3/11 (27%)&#160;&#160;2/12 (17%)&#160;&#160;Baseline characteristics: mean (min, max)&#160;&#160;n=11&#160;&#160;n=12&#160;&#160;Age&#160;&#160;12.1 (7, 19)&#160;&#160;13.1 (7, 21)&#160;&#160;HFMSE score&#160;&#160;47.6 (26, 63)&#160;&#160;51.3 (43, 62)&#160;&#160;# of nusinersen maintenance doses&#160;&#160;n/a&#160;&#160;5.6
              (2, 8)&#160;&#160;Majority maintained or improved57% (13/23) with &#8805;0-point increase39% (9/23) with &#8805;1-point increaseUp to 8-point increase observedResults contrast with declines typically observed with natural history of ambulatory patients&#160;&#160;Data on
              file. Scholar Rock, Inc. Cambridge, MA&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide49.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;&#160;&#160;Non-Ambulatory Type 2 Cohort (Age &#8805;2 years):Dose Response Observed in PD and Efficacy Data&#160;&#160;Mean
              (&#177;SEM) change from baseline&#160;&#160;20 mg/kg dose numerically offered greater HFMSE increasesthan 2 mg/kg dose across all timepointsDurability of effect observed through 12-months of treatment&#160;&#160;&#160;&#160;Greater target engagement and efficacy observed with
              20 mg/kg&#160;&#160;&#160;&#160;Both 2 mg/kg and 20 mg/kg doses yielded high levels oftarget engagement (&gt;100-fold increase from baseline)20 mg/kg offered relatively higher magnitude of
              targetengagement&#160;&#160;&#160;&#160;1&#160;&#160;10&#160;&#160;100&#160;&#160;1000&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0 28 56 84 112 140 168 196 224 252 280 308 336 364Time
              (days)&#160;&#160;Mean (&#177;SD) Latent Myostatin Concentration (ng/mL)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TOPAZ Cohort 3 (2 TO&#160;&#160;Apitegromab achieved robust target engagement10000&#160;&#160;Sizable increases in HFMSE achieved by patients on chronic maintenance nusinersen&#160;&#160;Data on file.
              Scholar Rock, Inc. Cambridge, MA&#160;&#160;49&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/7167b26bdf334dcc16847f8af392d836-a52445497ex99_1slide50.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;50&#160;&#160;&#160;&#160;&#160;&#160;Gilead fibrosis-focused TGF&#946; collaboration&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DRAGON Part A: dose escalation and
              continued follow-up&#160;&#160;Apitegromab Spinal Muscular Atrophy (SMA)&#160;&#160;SRK-181Immuno-Oncology and Oncology&#160;&#160;Preclinical/ Platform&#160;&#160;TOPAZ12M topline data&#160;&#160;Planned apitegromab Phase 3 program in SMA by year-end&#160;&#160;2021: Potential for Another
              Transformative Year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TOPAZ extension&#160;&#160;Continue to discover and advance preclinical programs&#160;&#160;Multiple opportunities for additional myostatin-related indications beyond SMA and muscular dystrophies&#160;&#160;Multiple additional
              opportunities: 1) SRK-181 in oncology; 2) latent TGF&#946;1 immune cell in IO; 3) latent TGF&#946;1 immune cell in oncology&#160;&#160;Gilead Fibrosis collaboration&#160;&#160;2022 and Beyond&#160;&#160;2021&#160;&#160;Q2&#160;&#160;Q3&#160;&#160;Q4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Latent TGF&#946;1 Immune Cell Immuno-Oncology and
              Oncology&#160;&#160;&#160;&#160;DRAGON Part B to initiate mid-year: multiple tumor typesMelanomaNSCLCUrothelial CarcinomaOther Solid Tumor Types&#160;&#160;ApitegromabOther Indications&#160;&#160;Multiple opportunities in muscular dystrophies, including Becker Muscular Dystrophy&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText"><br>
      </div>
    </font></div>
  <div style="text-align: center;"><font style="font-weight: bold;"> <br>
    </font></div>
</body>
</html>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/8326\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
